The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Cell transplantation in Parkinson's disease: how can we make it work?

På svenska

Author

Summary, in English

Previous open-label clinical trials have provided proof of principle that intrastriatal transplants of fetal dopaminergic neurons can induce substantial and long-lasting functional benefits in patients with Parkinson's disease. However, in two recent NIH-sponsored double-blind trials, functional improvements were only marginal and the primary endpoints were not met. Severe off-phase dyskinesias were observed in a significant proportion of the transplanted patients, raising doubts about the viability of the cell-transplantation approach. Here, we discuss the problems raised by the NIH-sponsored trials and point to several shortcomings that might explain the overall poor outcome, and we identify several crucial issues that remain to be resolved to develop cell replacement into an effective and safe therapy.

Publishing year

2005

Language

English

Pages

86-92

Publication/Series

Trends in Neurosciences

Volume

28

Issue

2

Document type

Journal article (comment)

Publisher

Elsevier

Topic

  • Neurosciences

Status

Published

Research group

  • Brain Repair and Imaging in Neural Systems (BRAINS)
  • Neurobiology

ISBN/ISSN/Other

  • ISSN: 1878-108X